The microbiome influence.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma.Oncoimmunology · 2026
   Review
2. The East Asian gut microbiome and its role in oncology: a narrative review.Singapore medical journal · 2025
   Review
3. Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy.Frontiers in immunology · 2023
   Review
4. The gut microbiome: what the oncologist ought to know.British journal of cancer · 2021
   Review

Corrections and comments

• Comment on
  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.2018
• Comment on
  Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.2018
• Comment on
  The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as